Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015-06-10
External Validation of the Benefit of Adjuvant Radiotherapy for Pathologic N1M0 Prostate Cancer.
Related Questions
Would you offer adjuvant radiation? (Dose? Target?) vs Salvage?
Would you add ADT? Would you add abiraterone?
Would the number of lymph nodes involv...
New answer by Radiation Oncologist at Center for Neurosciences (August 3, 2022)
@Daniel E. Spratt - What are your thoughts on the addition of Abiretarone to this patient population? The STAMPEDE trial was for intact prostate. Would insurance ever consider...